0
Startups & Venture·July 12, 2026·1 min read

Reed Jobs would rather talk about curing cancer than his last name

Share

A 17-person Yosemite team leaning into oncology as blockbuster patents expire means more capital chasing post-patent white space—companion diagnostics, delivery tech, and next-gen therapies. If you operate in healthcare or biotech tooling, expect sharper diligence around real clinical leverage, not just AI-on-biology narratives.

Startups & Venture

The Week’s 10 Biggest Funding Rounds: A Pair Of Billion-Dollar Deals For Cyber And AI Infrastructure Lead

Billion‑dollar rounds into AI infra and cybersecurity say two things: investors expect AI workloads to keep compounding, and they expect the attack surface to grow just as fast. If you’re building in the AI stack, assume capital is available for infra and security moats—differentiation will come from integration into real workloads, not raw scale alone.